5 recent trends in psychiatry that changed daily practice
Industry Buzz
I do believe that all physicians should be interested in both the physical health and mental health, the totality of the person.
—Ramaswamy Viswanathan, MD
This past year in psychiatry was filled with many small-but-meaningful, practice-changing shifts arriving at once: new FDA flexibilities, lifestyle psychiatry getting “real,” psychedelics maturing but meeting regulators, and measurement-heavy models coming out of APA.
Below, five developments redefining psychiatric care and general practice.
1. A busier FDA year for mental health
The first half of 2025 alone brought several FDA actions that make day-to-day care more workable. Consider the following, as summarized by HCPLive:[]
Expanded administration sites and faster induction for monthly buprenorphine (SUBLOCADE) in OUD
Esketamine (SPRAVATO) approved as the first monotherapy for treatment-resistant depression
A viloxazine (ADHD) label update with lactation data
The FDA’s acceptance of an sNDA for long-acting risperidone (UZEDY) in bipolar I disorder
Esketamine no longer has to “ride along” with an oral antidepressant; OUD treatment can be delivered in more places; and LAIs continue to expand their use from schizophrenia into bipolar disorder—all of which reduce nonadherence points.
Related: Finding the ‘right fit’ between psychiatrists and patients2. Lifestyle psychiatry becomes a headline theme
The APA president framed the 2025 Annual Meeting around “Lifestyle for Positive Mental and Physical Health,” stressing that movement, sleep, nutrition, and social connection should sit next to meds and therapy, not behind them.
“I do believe that all physicians should be interested in both the physical health and mental health, the totality of the person," said Ramaswamy Viswanathan, MD, outgoing APA president. []
Sessions also linked metabolic health to mood and cognition. Roger McIntyre, MD, reminded clinicians that insulin signaling is “a critical role in mood regulation and cognition.” []
Psychiatrists will be asked to measure and modify lifestyle factors with the same seriousness as dose adjustments, and to partner more closely with primary care and endocrine colleagues.
3. Psychedelic-assisted therapy: data strong, regulators cautious
By October 2025, reviews of psychedelic therapy were reporting high response and remission rates for psilocybin in depression, as well as solid Phase 3 data for MDMA-assisted therapy in PTSD, with 71% of participants in one trial no longer meeting PTSD criteria after three sessions. []
However, the FDA again asked for more Phase 3 work on MDMA given concerns about blinding, safety, and methodology in the existing studies. []
4. Measurement-heavy, tech-assisted psychiatry
Coverage from the 2025 APA meeting highlighted the use of plasma antipsychotic levels to answer questions such as “Is the patient taking it?” “Is the level therapeutic?” ”Do they metabolize differently?”
Some new approaches raised expectations that turnaround times will eventually be hours, not weeks. [] Jonathan M. Meyer, MD, put it plainly: “Patients with schizophrenia are among the most ill that many of us will ever see. Why would we not want all the information we can gather?”
5. Suicide prevention and chronic-risk frameworks get sharper
Igor Galynker, MD, PhD, presented the Narrative-Crisis Model to better map the transition from chronic suicidal risk to imminent risk. [] He emphasized the value of being able to do this without relying on a patient’s declaration of their suicidality.
“We have researched and created the model of suicidal behavior which does not rely on people telling you they are suicidal because they can’t in that state," he said.
Use of this model is actionable for inpatient, consultation-liaison (C-L), ED, and community teams. It pushes psychiatrists to document and intervene on crisis narratives, not just PHQ-9 item 9.
Read Next: Best of 2025: 5 major changes that redefined neurology